Alumis to Participate in Upcoming September Investor Conferences
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences in September 2024. The company, which focuses on developing oral therapies for immune-mediated diseases, will be present at five major healthcare and investment events:
1. Morgan Stanley Global Healthcare Conference (Sept. 5)
2. Wells Fargo Healthcare Conference (Sept. 6)
3. Baird Global Healthcare Conference (Sept. 11)
4. Cantor Fitzgerald Global Healthcare Conference (Sept. 17)
5. Stifel Immunology and Inflammation Virtual Summit (Sept. 18)
Alumis management will engage in various formats including fireside chats, presentations, and one-on-one investor meetings. Webcasts will be available for some events on the company's website.
Alumis Inc. (Nasdaq: ALMS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a diverse conferenze per investitori a settembre 2024. L'azienda, che si concentra sullo sviluppo di terapie orali per le malattie mediate dal sistema immunitario, sarà presente a cinque importanti eventi nel settore sanitario e negli investimenti:
1. Conferenza globale sulla salute di Morgan Stanley (5 settembre)
2. Conferenza sulla salute di Wells Fargo (6 settembre)
3. Conferenza globale sulla salute di Baird (11 settembre)
4. Conferenza globale sulla salute di Cantor Fitzgerald (17 settembre)
5. Summit virtuale su immunologia e infiammazione di Stifel (18 settembre)
La gestione di Alumis parteciperà a vari formati, tra cui chiacchierate informali, presentazioni e incontri individuali con gli investitori. I webcast saranno disponibili per alcuni eventi sul sito web dell'azienda.
Alumis Inc. (Nasdaq: ALMS), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en varias conferencias para inversores en septiembre de 2024. La compañía, que se centra en el desarrollo de terapias orales para enfermedades mediadas por el sistema inmunológico, estará presente en cinco eventos importantes de salud e inversión:
1. Conferencia Global de Salud de Morgan Stanley (5 de septiembre)
2. Conferencia de Salud de Wells Fargo (6 de septiembre)
3. Conferencia Global de Salud de Baird (11 de septiembre)
4. Conferencia Global de Salud de Cantor Fitzgerald (17 de septiembre)
5. Cumbre Virtual de Inmunología e Inflamación de Stifel (18 de septiembre)
La dirección de Alumis participará en varios formatos, incluidas charlas informales, presentaciones y reuniones individualizadas con inversores. Se dispondrá de webcast para algunos eventos en el sitio web de la empresa.
Alumis Inc. (Nasdaq: ALMS), 임상 단계의 생물약제회사인 Alumis Inc.는 2024년 9월에 여러 투자자 회의에 참여할 것이라고 발표했습니다. 면역 매개 질병을 위한 경구 치료제를 개발하는 데 중점을 둔 이 회사는 다섯 개 주요 의료 및 투자 행사에 참석할 예정입니다:
1. 모건 스탠리 글로벌 헬스케어 컨퍼런스 (9월 5일)
2. 웰스 파고 헬스케어 컨퍼런스 (9월 6일)
3. 베어드 글로벌 헬스케어 컨퍼런스 (9월 11일)
4. 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스 (9월 17일)
5. 스티펠 면역학 및 염증 가상 정상 회담 (9월 18일)
Alumis 경영진은 파이어사이드 채트, 발표, 개별 투자자 회의 등을 포함한 다양한 형식으로 참여할 것입니다. 일부 이벤트에 대한 웹캐스트는 회사 웹사이트에서 제공될 예정입니다.
Alumis Inc. (Nasdaq: ALMS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à plusieurs conférences d'investisseurs en septembre 2024. L'entreprise, qui se concentre sur le développement de thérapies orales pour les maladies médées par le système immunitaire, sera présente à cinq événements majeurs dans le secteur de la santé et des investissements :
1. Conférence mondiale sur la santé de Morgan Stanley (5 septembre)
2. Conférence sur la santé de Wells Fargo (6 septembre)
3. Conférence mondiale sur la santé de Baird (11 septembre)
4. Conférence mondiale sur la santé de Cantor Fitzgerald (17 septembre)
5. Sommet virtuel sur l'immunologie et l'inflammation de Stifel (18 septembre)
La direction d'Alumis participera à divers formats, y compris des discussions informelles, des présentations et des réunions individuelles avec les investisseurs. Des webcasts seront disponibles pour certains événements sur le site internet de l'entreprise.
Alumis Inc. (Nasdaq: ALMS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an mehreren Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen, das sich auf die Entwicklung von oralen Therapien für immunvermittelte Krankheiten konzentriert, wird an fünf bedeutenden Gesundheits- und Investitionsveranstaltungen teilnehmen:
1. Morgan Stanley Global Healthcare Conference (5. September)
2. Wells Fargo Healthcare Conference (6. September)
3. Baird Global Healthcare Conference (11. September)
4. Cantor Fitzgerald Global Healthcare Conference (17. September)
5. Stifel Immunology and Inflammation Virtual Summit (18. September)
Das Management von Alumis wird in verschiedenen Formaten teilnehmen, darunter informelle Gespräche, Präsentationen und persönliche Investorengespräche. Webcasts werden für einige Veranstaltungen auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September:
Morgan Stanley 22nd Annual Global Healthcare Conference
Thursday, September 5, 2024, 8:30 am ET
New York, NY
Format: fireside chat and one-on-one investor meetings
2024 Wells Fargo Healthcare Conference
Friday, September 6, 2024
Boston, MA
Format: one-on-one investor meetings only
Baird 2024 Global Healthcare Conference
Wednesday, September 11, 2024, 8:30 am ET
New York, NY
Format: presentation and one-on-one investor meetings; archived webcast replay on Investor Events page of Alumis website for 90 days following the conference
2024 Cantor Fitzgerald Global Healthcare Conference
Tuesday, September 17, 2024, 10:55 am ET
New York, NY
Format: fireside chat and one-on-one investor meetings; live webcast on Investor Events page of Alumis website, archived replay available for 90 days following the presentation
Stifel 2024 Immunology and Inflammation Virtual Summit
Wednesday, September 18, 2024, 10:00 am ET
Format: presentation
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies. Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, Alumis’ proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify its precision approach. Incubated by Foresite Labs and led by a team of industry veterans experienced in small-molecule compound drug development for immune-mediated diseases, Alumis is pioneering a precision approach to drug development to potentially produce the next generation of treatment to address immune dysfunction. For more information, visit www.alumis.com.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
FAQ
What investor conferences will Alumis (ALMS) attend in September 2024?
When is Alumis (ALMS) presenting at the Baird 2024 Global Healthcare Conference?
Will there be webcasts available for Alumis (ALMS) conference presentations?
What type of company is Alumis (ALMS)?
